SPY123-201 Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Spyre Therapeutics, Inc.
Start Date
October 13, 2025
End Date
June 30, 2030
Administered By
Medicine, Gastroenterology
Awarded By
Spyre Therapeutics, Inc.
Start Date
October 13, 2025
End Date
June 30, 2030